Sarepta Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Sarepta Therapeutics heeft een totaal eigen vermogen van $1.1B en een totale schuld van $1.2B, wat de schuld-eigenvermogensverhouding op 113.9% brengt. De totale activa en totale passiva bedragen respectievelijk $3.4B en $2.3B. De EBIT Sarepta Therapeutics is $38.0M waardoor de rentedekking -2.7 is. Het heeft contanten en kortetermijnbeleggingen van $1.5B.
Belangrijke informatie
113.9%
Verhouding schuld/eigen vermogen
US$1.23b
Schuld
| Rente dekkingsratio | -2.7x |
| Contant | US$1.46b |
| Aandelen | US$1.08b |
| Totaal verplichtingen | US$2.35b |
| Totaal activa | US$3.42b |
Recente financiële gezondheidsupdates
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Recent updates
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $2.7B ) SRPT } overtreffen de korte termijn passiva ( $688.5M ).
Langlopende schulden: De kortetermijnactiva SRPT ( $2.7B ) overtreffen de langetermijnschulden ( $1.7B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: SRPT heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van SRPT is de afgelopen 5 jaar gestegen van 39.2% naar 113.9%.
Schuldendekking: De operationele kasstroom van SRPT is negatief, waardoor de schuld niet goed gedekt is.
Rentedekking: SRPT verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.